Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US FDA Proposes New Medtech Fee Categories

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration is proposing to create new user fees to pay for de novo classification reviews and pre-submission consultations, among other reforms, as part of the next user fee program (MDUFA IV)1.